These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 21691817)

  • 1. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
    Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
    Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
    Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
    Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
    Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
    J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
    Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
    Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: A randomized, controlled clinical trial.
    Peng N; Yu M; Yang G; Fu Q; Xu Y; Yu J; Liu Q; Li C; Xu W; Zhang Y; Ma C; Yang L; Yu R; Wang X
    Breast; 2018 Feb; 37():18-27. PubMed ID: 29059538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
    Sergi G; Pintore G; Falci C; Veronese N; Berton L; Perissinotto E; Basso U; Brunello A; Monfardini S; Manzato E; Coin A
    J Bone Miner Metab; 2012 Jul; 30(4):461-7. PubMed ID: 22160398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chinese Medicine Yishen Jiangu Granules () on Aromatase Inhibitor-Associated Musculoskeletal Symptoms.
    Zhang X; Peng N; Yu MW; Zhang GL; Sun X; Yang GW; Li C; Yang L; Wang XM
    Chin J Integr Med; 2018 Nov; 24(11):867-872. PubMed ID: 30062634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
    Singh S; Cuzick J; Mesher D; Richmond B; Howell A
    Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.
    Liu P; Yang DQ; Xie F; Zhou B; Liu M
    Genet Mol Res; 2014 Jul; 13(3):5285-91. PubMed ID: 25078584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
    Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
    Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer.
    Lester JE; Dodwell D; Purohit OP; Gutcher SA; Ellis SP; Thorpe R; Horsman JM; Brown JE; Hannon RA; Coleman RE
    Clin Cancer Res; 2008 Oct; 14(19):6336-42. PubMed ID: 18829518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the traditional Chinese medicine Yi Shen Jian Gu granules on aromatase inhibitor-associated musculoskeletal symptoms: a study protocol for a multicenter, randomized, controlled clinical trial.
    Peng N; Zhang Y; Ma C; Yu MW; Yang GW; Fu Q; Xu WR; Wang XM
    Trials; 2014 May; 15():171. PubMed ID: 24885324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
    Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
    Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors.
    Bao T; Cai L; Giles JT; Gould J; Tarpinian K; Betts K; Medeiros M; Jeter S; Tait N; Chumsri S; Armstrong DK; Tan M; Folkerd E; Dowsett M; Singh H; Tkaczuk K; Stearns V
    Breast Cancer Res Treat; 2013 Feb; 138(1):167-74. PubMed ID: 23393007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
    Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
    Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R; Hannon RA; Cuzick J; Dowsett M; Clack G; Adams JE;
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.